
    
      This study is designed to support the optimal use of mTOR-inhibitor by providing data for the
      safe and effectiveness use with sirolimus. This study will take into account effectiveness
      aspects such as malignancy-free survival cancer by reducing the overall exposure to
      calcineurin inhibitor.
    
  